SAN DIEGO and GREENWOOD VILLAGE, Colo., Aug. 28, 2014 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Ampio Pharmaceuticals, Inc. breached their fiduciary duties to shareholders. Ampio develops therapies for the treatment of prevalent inflammatory conditions in the United States.
View this press release on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/ampio-pharmaceuticals-inc
Ampio Announces Delay in Ampion Results Due to Flaw in Phase III Testing
On August 21, 2014, the share price of Ampio's stock dropped 24% after the company announced that the recent phase III study of the drug Ampion may have been flawed and final results would be delayed. In a letter to shareholders on August 25, 2014, the company explained that during the study there was a point where the chemical being tested allegedly froze, which is believed to have affected the level of active ingredients in the dosage of Ampion.
Ampio Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, DDonahue@robbinsarroyo.com, or via the shareholder information form on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a similar outcome.